MindBio Therapeutics Corp. (CNSX: MBIO)
Health Care · Biotechnology · CA
CA$0.21
-16.00% today · -89.5% 1Y
MindBio Therapeutics Corp. (CNSX: MBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.10M.
Over the last twelve months the share price has lost 89.5%, trading between 0.20 and 4.00.
Tweenvest scores MindBio Therapeutics Corp. across four factors: quality 4/100. Its strongest factor is quality.
MBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.10M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.13
- Dividend yield
- —
- Beta (5Y)
- -1.29
- 52-week high
- CA$4.00
- 52-week low
- CA$0.20
- Avg volume (3M)
- —
- Shares outstanding
- 7.28M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.